Zacks Research Estimates Haemonetics’ Q1 Earnings (NYSE:HAE)

Haemonetics Corporation (NYSE:HAE) – Analysts at Zacks Research raised their Q1 2028 earnings estimates for shares of Haemonetics in a research report issued to clients and investors on Wednesday, January 28th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $1.39 per share for the quarter, up from their previous estimate of $1.38. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The business had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same quarter last year, the company posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.

Several other analysts have also recently commented on HAE. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Barrington Research boosted their target price on shares of Haemonetics from $90.00 to $93.00 and gave the stock an “outperform” rating in a research note on Monday, January 12th. CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. Finally, Robert W. Baird upped their price objective on Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $84.40.

Haemonetics Stock Down 0.2%

NYSE HAE opened at $65.93 on Friday. The stock’s 50 day simple moving average is $78.72 and its 200 day simple moving average is $65.57. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The firm has a market cap of $3.09 billion, a PE ratio of 19.28, a price-to-earnings-growth ratio of 1.37 and a beta of 0.29. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its stake in Haemonetics by 372.8% during the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares in the last quarter. Millennium Management LLC increased its position in shares of Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after acquiring an additional 755,592 shares in the last quarter. Norges Bank acquired a new stake in shares of Haemonetics during the second quarter worth $36,822,000. Invenomic Capital Management LP lifted its position in Haemonetics by 1,691.5% in the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after acquiring an additional 470,502 shares in the last quarter. Finally, SG Capital Management LLC boosted its stake in Haemonetics by 92.5% in the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after purchasing an additional 435,660 shares during the period. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.